Australian biotech co buys into foetal cell recovery
This article was originally published in Clinica
Executive Summary
Australian public company Genetic Technologies is investing $2.65 million in Fort Collins, Colorado-based Cytomation, a company whose work on foetal cell recovery research first drew it to the Australian company's notice. It already held a very small (0.5%) of the equity in Cytomation since February, but three further investments have now brought its total holdings to 10% approximately.
You may also be interested in...
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
P&G Restores Volume Growth In Beauty, Grooming After Pricing Run
Procter & Gamble reports strong consumer spending in the US and Europe after a 3% increase in product pricing over the past year. Dragging on fiscal third-quarter results, sales of SK-II in China fell 30% for the January-March period, while lower incidence of cough and cold impacted Health Care performance.
BMS Has A Strong Pipeline, But Access Challenges Remain
Bristol Myers Squibb’s head of major markets, Monica Shaw, wants to improve patients’ access to lifesaving therapies. And the group has several new products ready to roll.